Ipratropium
From Wikipedia, the free encyclopedia
| |
| Ipratropium
| |
| Systematic (IUPAC) name | |
| [8-methyl-8-(1-methylethyl)- 8-azoniabicyclo[3.2.1] oct-3-yl] 3-hydroxy-2-phenyl-propanoate | |
| Identifiers | |
| CAS number | 60205-81-4 |
| ATC code | R01AX03 R03BB01 |
| PubChem | 43232 |
| DrugBank | APRD00537 |
| Chemical data | |
| Formula | C20H30NO3 |
| Mol. weight | 332.457 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 0 to 9% in vitro |
| Metabolism | Hepatic |
| Half life | 2 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
POM(UK) |
| Routes | inhalation |
Ipratropium is an anticholinergic drug (trade name: Atrovent®) administered by inhalation for the treatment of obstructive lung diseases. It acts by blocking muscarinic receptors in the lung, inhibiting bronchoconstriction and mucus secretion.
[edit] Sources
- Brenner, G. M. (2000). Pharmacology. Philadelphia, PA: W.B. Saunders Company. ISBN 0-7216-7757-6
- Canadian Pharmacists Association (2000). Compendium of Pharmaceuticals and Specialties (25th ed.). Toronto, ON: Webcom. ISBN 0-919115-76-4
[edit] External links
| Medications commonly used in asthma and COPD (primarily R03) edit | ||
|---|---|---|
| Anticholinergics: |
Ipratropium, Tiotropium | |
| Short acting β2-agonists: | ||
| Long acting β2-agonists (LABA): | Clenbuterol, Formoterol, Salmeterol | |
| Corticosteroids: | ||
| Leukotriene antagonists: | ||
| Xanthines: | ||
| Mast cell stabilizers: | ||
| Combination products: |
Budesonide/formoterol, Fluticasone/salmeterol, Ipratropium/salbutamol | |
